Product Development and Clinical Trials - GeoVax is developing immunotherapies and vaccines for infectious diseases and solid tumor cancers, with ongoing clinical trials for a next-generation Covid-19 vaccine and gene-directed therapy for advanced head and neck cancer[46]. - A Phase 2 trial for GEO-CM04S1 is evaluating its safety and efficacy as a Covid-19 vaccine in high-risk immunocompromised patients, showing high immunogenicity with neutralizing antibody responses[48]. - The first lot of GEO-CM04S1 was produced using a commercial manufacturing platform, marking a significant milestone in the MVA-based vaccine manufacturing process[52]. - Gedeptin is undergoing a Phase 1/2 trial for advanced head and neck cancer, with interim data indicating safety and tumor growth impairment in most patients[55]. - The company is in advanced discussions with BARDA for potential funding related to Project NextGen, aimed at developing innovative vaccines and therapeutics[73]. Financial Performance - The company has not generated any revenues to date from product sales, indicating a focus on research and development efforts[59]. - Net loss for the three months ended March 31, 2024, was $5,850,132, an increase of $1,812,216 from the net loss of $4,037,916 in 2023[66]. - Cash and cash equivalents decreased to $768,859 as of March 31, 2024, down from $6,452,589 as of December 31, 2023[69]. - Net cash used in operating activities was $5,683,730 for the three months ended March 31, 2024, compared to $3,762,872 in 2023[69]. - The company has not generated any product revenue to date and anticipates continued losses as it seeks regulatory approvals and commercializes product candidates[71]. Research and Development Expenses - Research and development expenses are expected to increase significantly as GeoVax advances its product candidates through clinical trials, particularly for Gedeptin and GEO-CM04S1 programs[60]. - Research and development expenses increased by $1,606,539 (57%) to $4,425,728 for the three months ended March 31, 2024, compared to $2,819,189 in 2023, primarily due to clinical trial costs and personnel expenses[66]. General and Administrative Expenses - General and administrative expenses are expected to rise as the company prepares for potential commercialization and maintains compliance with regulatory requirements[61]. - General and administrative expenses rose by $5,928 (0.4%) to $1,457,353 for the three months ended March 31, 2024, compared to $1,451,425 in 2023[67]. Funding and Capital Requirements - A bridge financing was conducted on May 10, 2024, issuing $150,000 in unsecured promissory notes to board members and senior management, with a 15% annual interest rate[72]. - The company expects to need substantial additional funding to support ongoing operations and product development[75]. - Future capital requirements will depend on various factors, including clinical trial costs, manufacturing expenses, and regulatory approval timelines[79]. Intellectual Property - The U.S. Patent and Trademark Office issued multiple patents to GeoVax in February 2024, covering compositions for malaria and Marburg virus, enhancing the company's intellectual property portfolio[56][57]. Market Environment - The company operates in a highly competitive and regulated environment, with ongoing risks and uncertainties affecting future performance and financial results[45]. Stock and Compliance - A reverse stock split of 1-for-15 was executed to regain compliance with Nasdaq listing requirements, converting every fifteen shares into one[58].

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC. During his presentat ...

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024. Presentation Details: Presenter:       David Dodd, Chairman & CEODate/Time:      March 18, 2024, 2:30 pm PTLocation:         Dana Point, CAWebcast Li ...

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company's MVA-based vaccines, with the release of its fi ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Max Gadicke - Stern, IR David Dodd - Chairman and CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer John Sharkey - VP, Business Development Conference Call Participants Laura Suriel - Alliance Global Partners Jeffrey Kraws - Crystal Research Robert LeBoyer - NOBLE Capital Markets Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Operator Good afternoon, and welcome, eve ...

Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, February 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023. "2023 marked another year of advancement of our ongoing clinical programs for GEO-CM04S1, our ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1900 Lake Park Drive, Suite 380 ...

ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024. Presentation Details:Presenter:        David Dodd, Chairman & CEODate/Time:       February 26, 2024, 4:15 pm ETLocation:          New ...

Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company's intellectual property assets. The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the a ...

ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc.  (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1-for-15. The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid ...